Literature DB >> 1948102

Lupus erythematosus in the 1980s: a survey of 570 patients.

M Pistiner1, D J Wallace, S Nessim, A L Metzger, J R Klinenberg.   

Abstract

Five hundred seventy lupus erythematosus patients observed in a private practice between 1980 and 1989 were surveyed. Fifty-five percent were diagnosed after 1980. Five hundred three fulfilled criteria for systemic lupus erythematosus ( [SLE]; 464 idiopathic, 23 overlap, 16 drug-induced) and 67 had biopsy-documented cutaneous (discoid) lupus. In the idiopathic SLE group, symptoms began at a mean age of 31 years and patients were observed for a mean of 6 years. Findings in idiopathic SLE patients were (1) 27% have a family history of autoimmune disease; (2) nephritis patients without nephrotic syndrome rarely develop renal failure (4%); (3) nephrotic syndrome patients are relatively cyclophosphamide-resistant; (4) organ-threatening disease is present in 54%; and (5) 13% of women who become pregnant are recurrent aborters and 26% never conceive. In an analysis of cohort data, 5- and 10-year survivals were 97% +/- 2% and 93% +/- 3%, respectively. Additionally, men and patients with renal disease or thrombocytopenia had a poorer prognosis. Blacks had similar clinical findings and survival to whites. Approximately 50% of deaths were from active disease and 50% from complications of therapy. Prolonged survival has resulted from new diagnostic procedures and serologic tests, and improved antibiotics and antihypertensive agents, as well as more efficacious treatment modalities.

Entities:  

Mesh:

Year:  1991        PMID: 1948102     DOI: 10.1016/0049-0172(91)90057-7

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  52 in total

Review 1.  Initial management of proliferative lupus nephritis: to cytotoxic or not to cytotoxic?

Authors:  H M Belmont
Journal:  Curr Rheumatol Rep       Date:  1999-12       Impact factor: 4.592

2.  Prophylactic use of antibiotics and immunisations in patients with SLE.

Authors:  W R Gilliland; G C Tsokos
Journal:  Ann Rheum Dis       Date:  2002-03       Impact factor: 19.103

Review 3.  Shared autoimmunity: the time has come.

Authors:  Donato Alarcón-Segovia
Journal:  Curr Rheumatol Rep       Date:  2004-06       Impact factor: 4.592

Review 4.  Current topics in human SLE genetics.

Authors:  Maida Wong; Betty P Tsao
Journal:  Springer Semin Immunopathol       Date:  2006-08-29

5.  Upregulated expression of STAT3/IL-17 in patients with systemic lupus erythematosus.

Authors:  Shih-Yao Chen; Ming-Fei Liu; Pin-Yu Kuo; Chrong-Reen Wang
Journal:  Clin Rheumatol       Date:  2019-02-15       Impact factor: 2.980

6.  EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis.

Authors:  C-S Yee; C Gordon; C Dostal; P Petera; J Dadoniene; B Griffiths; B Rozman; D A Isenberg; G Sturfelt; O Nived; J H Turney; A Venalis; D Adu; J S Smolen; P Emery
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

7.  Systemic lupus erythematosus in Saudi patients.

Authors:  S R Alballa
Journal:  Clin Rheumatol       Date:  1995-05       Impact factor: 2.980

8.  [Inflammatory diseases with liver and joint involvement. A differential diagnostic challenge].

Authors:  M Sebode; C Schramm; A W Lohse
Journal:  Internist (Berl)       Date:  2013-04       Impact factor: 0.743

9.  Cross-sectional analysis of a collaborative Web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients.

Authors:  Siamak Moghadam-Kia; Katherine Chilek; Elizabeth Gaines; Melissa Costner; Mathew E Rose; Joyce Okawa; Victoria P Werth
Journal:  Arch Dermatol       Date:  2009-03

Review 10.  Review: Male systemic lupus erythematosus: a review of sex disparities in this disease.

Authors:  L-J Lu; D J Wallace; M L Ishimori; R H Scofield; M H Weisman
Journal:  Lupus       Date:  2009-11-27       Impact factor: 2.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.